NCT05238831 2024-01-23SMMART Adaptive Clinical Treatment (ACT) TrialOHSU Knight Cancer InstitutePhase EARLY_PHASE1 Withdrawn
NCT00383760 2017-10-20Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer PatientsNational Cancer Institute (NCI)Phase 2 Completed15 enrolled 11 charts